UBS O'Connor’s Cytokinetics CYTK Stock Holding History

UBS O'Connor’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,993	Closed	-$181K	–	566
2024 Q1	$210K	Buy	+2,993	New	+$231K	0.01%	396

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

UBS O'Connor's CYTK Position: Q2 2024 in Review

UBS O'Connor sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 2,993 shares — an estimated $181K sold.

UBS O'Connor first reported a position in CYTK in Q1 2024 and held it in 1 quarter. The position peaked at $210K in Q1 2024. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

UBS O'Connor reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
UBS O'Connor sold 2,993 Cytokinetics shares in Q2 2024, an estimated $181K.
UBS O'Connor first reported a position in Cytokinetics in Q1 2024 and held it in 1 quarter.
UBS O'Connor's Cytokinetics position peaked at $210K in Q1 2024.
343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.